Tab. 1.
Plackett-Burman design for 11 factors. % of nimotuzumab binding in both A 431 and NCI-H125 cell lines.
| Factor | % of Binding | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||
| Exp. | A | B | C | D | E | F* | G | H | I | J | K | A431 | H125 |
| 1 | + | + | − | + | + | + | − | − | − | + | − | 99,73 | 99,73 |
| 2 | − | + | + | − | + | + | + | − | − | − | + | 98,73 | 97,80 |
| 3 | + | − | + | + | − | + | + | + | − | − | − | 99,23 | 98,70 |
| 4 | − | + | − | + | + | − | + | + | + | − | − | 99,23 | 99,47 |
| 5 | − | − | + | − | + | + | − | + | + | + | − | 99,73 | 99,93 |
| 6 | − | − | − | + | − | + | + | − | + | + | + | 99,83 | 100,00 |
| 7 | + | − | − | − | + | − | + | + | − | + | + | 99,57 | 99,70 |
| 8 | + | + | − | − | − | + | − | + | + | − | + | 99,60 | 98,13 |
| 9 | + | + | + | − | − | − | + | − | + | + | − | 99,87 | 99,37 |
| 10 | − | + | + | + | − | − | − | + | − | + | + | 99,83 | 100,00 |
| 11 | + | − | + | + | + | − | − | − | + | − | + | 99,87 | 98,20 |
| 12 | − | − | − | − | − | − | − | − | − | − | − | 97,73 | 98,43 |
|
| |||||||||||||
| Average | 99,41 | 99,12 | |||||||||||
| RSD | 0,63 | 0,82 | |||||||||||
Exp…No of experiments;
+…High level;
−…Low level;
*
…Dummy factor.